ARA-290 vs Pentosan (Joint Pain)
A side-by-side research comparison of ARA-290 and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | Pentosan (Joint Pain) |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Pentosan Polysulfate Sodium (Cartrophen) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | FDA Approved (interstitial cystitis) / Veterinary approved |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects. |
| Molecular weight | ~1257 Da | ~4000-6000 Da (average) |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | ~24 hours |
| Bioavailability | High via subcutaneous injection | ~6% oral; ~100% subcutaneous |
| Typical dose | 1-4 mg per dose | 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day |
| Frequency | Daily during a course | Weekly SC injections (4-6 course) or daily oral |
| Route | Subcutaneous injection | Subcutaneous injection or oral capsule |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
Pentosan (Joint Pain) reported benefits
- Cartilage protection and repair
- Reduced joint inflammation
- Improved synovial fluid
- Disease-modifying (not just symptomatic)
- Reduced bone marrow edema
- Alternative to corticosteroid injections
Related comparisons
Research and educational reference only. Not medical advice.